Quantifying Age-Related Myelin Breakdown with MRI: Novel Therapeutic Targets for Preventing Cognitive Decline and Alzheimer's Disease
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Myelin plays an essential role in brain structure and function and the human brain is uniquely dependent on the elaboration of this late invention of evolution. Our brain has the most extensive and protracted process of myelination that extends to approximately age 50 in cortical regions that have the highest risk for developing Alzheimer's disease (AD) pathology. This myelin-centered model of the human brain asserts that unique vulnerabilities of myelin, especially late-developed myelin, and the oligodendrocytes that produce it are directly pertinent to many uniquely human neuropsychiatric diseases including late-life neurodegenerative disorders such as AD. Magnetic resonance imaging (MRI) technology permits the in vivo assessment of the roughly quadratic (inverted U) lifelong trajectory of human myelin development and its subsequent breakdown. There is close agreement between neuropsychology, neuropathology, and imaging measures suggesting that the process of myelin breakdown begins in adulthood, accelerates as aging progresses, and underlies both age-related cognitive declines and the most powerful risk factor of dementia-causing disorders such as AD: age. This myelin-centered model together with the technology that makes it possible to measure the trajectory of myelin breakdown provide a framework for developing novel treatments, as well as assessing efficacy of currently available treatments, intended to slow or reverse the breakdown process in both clinically healthy as well as symptomatic populations. Such treatments can be expected to have a wide spectrum of efficacy and impact multiple human disease processes including potentially slowing brain aging and thus provide opportunities for primary prevention of age-related degenerative disorders such as AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease
Bartzokis, G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.03.001 · Cited by 968 · cited 10×
“Cells that underwent differentiation and produced their myelin sheaths later in life and oligodendrocyte precursors in the process of differentiationaremost vulnerable [1,2].”
InfluentialSelf-citationApoE genotype accounts for the vast majority of AD risk and AD pathology
Raber, J., Huang, Y., & Ashford, J. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.023 · Cited by 599
The effects of normal aging on myelin and nerve fibers: a review
Peters, A. (2002) · Journal of Neurocytology · doi:10.1023/a:1025731309829 · Cited by 577
Bartzokis, G., Sultzer, D., Lu, P. H., Nuechterlein, K. H., Mintz, J., & Cummings, J. L. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.09.005 · Cited by 363
Self-citation
Cited by
Trajectories of brain aging in middle-aged and older adults: Regional and individual differences
Raz, N., Ghisletta, P., Rodrigue, K. M., Kennedy, K. M., & Lindenberger, U. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.03.020 · Cited by 630
Magnetic Resonance Imaging of Myelin
Laule, C., Vavasour, I. M., Kolind, S. H., Li, D. K. B., Traboulsee, T. L., Moore, G. R. W., & MacKay, A. L. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.05.004 · Cited by 334
Neuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
Desai, M. K., Sudol, K. L., Janelsins, M. C., Mastrangelo, M. A., Frazer, M. E., & Bowers, W. J. (2009) · Glia · doi:10.1002/glia.20734 · Cited by 266
“Studies of affected areas in the AD brain, including the hippocampus and entorhinal cortex, suggest that the regions most vulnerable to AD pathogenesis exhibit the most protracted course of myelination (Bartzokis, 2004; Bartzokis et al., 2004; Duyckaerts, 2004).”
BackgroundAssociation of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease
Dean, D. C., Hurley, S. A., Kecskemeti, S. R., O’Grady, J. P., Canda, C., Davenport-Sis, N. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Asthana, S., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3232 · Cited by 252
Metadata
- Authors
- Bartzokis, G., Lu, P. H., & Mintz, J.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2005-01-20
- Volume
- 6
- Issue
- s6
- Pages
- S53-S59
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W123354058
- Cited by
- 78
- References
- 4
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.